Byondis

#AACR2026 takeaway: ADCs need real differentiation — novel mechanisms, better selectivity, and smarter approaches to resistance. That is what we're building with our platform technologies designed to expand what targeted cancer medicines can do.

Next week our Senior Director Business Development Ivo Grgic will be heading to Swiss Biotech Day. If you are also attending and would like to connect, reach out to BD@Byondis.com. #ADCs #SwissBiotechDay

Next week, our CEO, Christoph Korpus, will be heading to Prague to present at #BioEquityEurope 2026. If you are also attending and would like to connect, reach out to BD@Byondis.com or via the partneringONE™ platform. #ADCs #Partnering #BioEquity2026

Our Project Leader Mary van Helden discusses Byondis' innovative immunostimulatory phosphonate ADCs with Lauren Coyle, @Bio_Insights. Learn more about the interview here: insights.bio/bioconjugate-i… #Innovation #AntibodyDrugConjugates

Join our Chief Science Officer @Wim Dokter at the @AACR Annual Meeting as he presents two posters showcasing Byondis’ technology. Reach out if you would like to meet the #Byondis team: BD@Byondis.com #Innovation #AntibodyDrugConjugates

Our CEO Christoph Korpus is heading to the @AACR #Oncology Industry Partnering Event in San Diego this week, ahead of the #AACR Annual Meeting. Reach out if you’ll be there and would like to meet the #Byondis team: BD@Byondis.com #Innovation #AntibodyDrugConjugates

Today we announce the #appointment of Dr. Christoph Korpus as our new CEO. In his new role, he will guide the advancement of our proprietary #ADC platforms as we work to deliver breakthrough solutions for people living with cancer. Read more: businesswire.com/news/home/2026…

Two abstracts highlighting the science behind our innovative ADC technology platforms have been selected as poster presentations at the American Association for Cancer Research Meeting. #AACR26 #AntibodyDrugConjugates #ADCs #OncologyResearch #Oncology #Byondis #MakeHopeReal

Byondis will be at #BioEuropeSpring! Please reach out if you are interested in meeting with Ivo and our team to discuss strategic collaborations, licensing opportunities, and other partnership possibilities: BD@Byondis.com. #BIOEurope #ADCInnovation #AntibodyDrugConjugates #ADCs

📣 Bas Kokke, PhD, Principal Scientist of Downstream Processing, will be presenting at the BioProcessing Summit 2026 on "Viral Clearance and Removal of Host-Cell Proteins" an important contribution to the development of innovative compounds like Byondis' work with (masked) ADCs.

🌟As part of International Women’s Day, we celebrate Mary, Eva and Astrid and all the women across our organization and throughout the biotech community who are advancing science and working toward a future where more patients have better options. #IWD2026 #WeAreByondis

We’re looking forward to a presentation by Byondis' Director of Analytical Development & Quality Control, Eef Dirksen, at this week's World ADC meeting on Wednesday, February 25th at 12:00 pm! #WorldADC #ADCInnovation #ADC #WeAreByondis #Byondis #OncologyResearch

At World ADC London, lead scientist, Renier Heijkants, will present our antifolate platform and its differentiated, validated mechanism of action. ➡️Learn more about Byondis' innovative ADC technology platforms: bit.ly/4r50ghw #WorldADC #AntifolateADC #Byondis

📣 Looking forward to World ADC London! At Byondis, we’re focused on unlocking the full potential of ADCs through our ADC technology platforms combining differentiated payloads with state-of-the-art linker & conjugation technologies & improved targeting strategies. #WorldADC

📣Mark Eggink, PhD, Principal Scientist, Analytical Development & Quality Control, will be presenting at the 2026 AQbD Symposium on updates to ICH Q2 and Q14 & the importance of integrating Analytical Quality by Design (AQbD) early in the analytical method lifecycle. #Byondis

📣 We are pleased to announce that Maarten Nieboer, PhD, has been appointed to Chief Technology Officer and member of the Leadership Team. We’re excited for the impact he will make across our fully integrated business to deliver breakthrough oncology solutions. #WeAreByondis

As 2025 closes, we want to recognize & thank our team, partners & the scientific community. Everything we do is guided by a single purpose: making meaningful treatment advances for patients. That purpose continues to shape our ambitions as we look ahead to 2026. Happy holidays!

📣 Today we announced a strategic transformation to focus R&D efforts on our novel antibody-drug conjugate (ADC) technology platforms. ➡️ Read the press release: bit.ly/4qn2Grh ➡️ Learn more about our novel technology platforms: bit.ly/4q2FjTw #ADCInnovation

📣 This week, our Chief Scientific Officer, Wim Dokter, PhD, will be speaking at the Dutch Life Sciences Conference, where he will present on Byondis’ antibody drug conjugate (ADC) technology platforms. ➡️ Learn more about the session and the event: lnkd.in/eFAhmdFz

Proud to partner with World ADC San Diego 2025 as we advance our innovative platforms of novel immune-stimulating and cytotoxic payloads and tumor-specific masking technology to overcome resistances and increase the therapeutic index of new and established ADCs and novel formats.